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Introduction: Natural killer (NK) cells are a promising tool for
adoptive immunotherapy in many disease settings. The avail-
ability of large quantities of functionally effective NK cells
represents oneof themajor challenges for immunotherapeutic
trials, and amajor objective of our laboratory is to enhance NK
cell number and function ex vivo for subsequent adoptive
immunotherapy. We previously published a robust approach
for ex vivo propagation of NK cells that has been validated for
healthy donor (Denman, 2012) and patient peripheral blood
(Liu, 2013), cord blood (ASH 2012), and embryonic/pleur-
ipotent stem cell sources (Knorr 2013) and has the potential to
generate far more NK cells than can be infused at one time.
Cryopreservation of NK cells provides signiﬁcant advantages
over infusion of fresh products by 1) reducing timing con-
straints in matching GMP manufacturing to patient need, 2)
enabling multiple infusions from single large-scale expan-
sions, and3)ensuringuniformcharacteristics foraliquots, all of
which are essential for generating off-the-shelf products.
However, NK cells are known to have poor survival and func-
tion after cryopreservation, and thiswas recently conﬁrmed in
clinical trials using standard clinical GMP cryopreservation
media containing Plasmalyte, dimethyl sulfoxide (DMSO), and
human serum albumin (HSA). In contrast, our preclinical data
with expanded NK cells cryopreserved in media, fetal bovine
serum (FBS) and DMSO showed excellent function and no
signiﬁcant difference between fresh and frozen cells (Liu,
2013). Therefore, we hypothesized that serum may provide
protective factors for NK cells during cryopreservation.
Methods: NK cells from four healthy donors were expanded
withweekly addition of irradiated K562 Clone9.mbIL21 feeder
cells as previously described. After three weeks, cells were
cryopreserved with freezing media of 40% Plasmalyte and 10%
DMSO, with varying ratios of HSA and human AB serum (hAB)
comprising the remainder. Cryopreserved NK cells were
thawed and assessed for cell recovery, viability, proliferation,
and function at 3, 24, 48, 72,120, 168 hours after thawing.
Cytotoxicity was determined against 721.221 target cells.
Results: A linear relationship was observed between hAB
content and recovery, viability, and cytotoxicity, plateauing
at 40% hAB. Unstimulated proliferation after thawing was
associated with higher hAB content, but re-stimulation with
Clone9.mbIL21 was similar in all conditions.
Conclusion: In the present study, we aimed to establish the
beneﬁt of including serum incryopreservationof expandedNK
cell. We conﬁrmed a signiﬁcant effect in preserving viability,
cytotoxicity, andproliferation, justifying its use inclinical trials.Baseline scan
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Background: Allogeneic transplantation is associated with
both GvL and GvHD. Elimination of donor T cells results in
less GvHD, but also less GvL and engraftment. To eradicate
infused T cells if GvHD develops, our suicide gene based
therapy uses a CD34-Herpes Simplex Virus-1-thymidine ki-
nase (CD34-TK75) chimera (Rettig et al, Mol Ther 2003 and J
Immunol 2006). We enrich and purify retrovirally trans-
duced cells via cell surface expression of the extracellular
domain of CD34. Modiﬁed TK75 both mediates cell suicide
upon treatment with ganciclovir and enables tracking of
modiﬁed cells that entrap the substrate, [18CT/CT.
Methods: Following production and release testing of CD34-
TK75 transduced and afﬁnity-puriﬁed T cells (88-98.8%
CD34+), we began a phase I pilot and feasibility study. Cells
were infused as a DLI (0.1-1.3 x 106 CD34-TK75+ T cells/kg)
into 8 patients (relapsed after allo-HSCT). Since no toxicities
were observed during treatment of our ﬁrst 2 patients, we
initiated trafﬁcking studies using [18F]-FHBG-PET/CT imaging
at baseline, d15, and d30 after infusion of CD34TK75+ T cells
in patients 3-8.
Results: No acute toxicities were associated with adminis-
tering either genetically modiﬁed T cells or [18F]FHBG. Using
real-time quantitative PCR, we detected the CD34-TK75
transgene in the circulating CD34-TK75+ T cells of all but one
patient. GvHD developed in only one patient (grade III GI)
who did not respond to a 10 day treatment with I.V. ganci-
clovir (10 mg/kg). CD34-TK75 transgene could not be
detected in the peripheral blood of this patient at the time of
GvHD. Patient samples were also tested for replication
competent retrovirus and for integration sites both by Liga-
tion Mediated-PCR and hybrid capture. Baseline levels of
[18F]FHBG were low, primarily characterized by renal excre-
tion, which should permit detection of T cell expansion in the
lymphoid organs or intestines. However, pharmacokinetics
of the radiolabel were similar in the one patient that did and
those that did not develop GvHD (Fig. 1). In parallel experi-
ments, NOD/SCIDg mice were injected (i.o.) with 2 x 106
CD34-TK75+ T cells (patients 2-8; n¼2 mice per donor).
Control mice received conditioning only. Using micro-PET/CT
